SCHEMBL104964

SCHEMBL104964

CCC(C)C(=O)CCc1ccc(O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.49
KDM4E B2RXH2 3/20 0.49
CYP19A1 P11511 2/20 0.49
ALDH1A1 P00352 2/20 0.49
LMNA P02545 2/20 0.49
TP53 P04637 2/20 0.49
CYP3A4 P08684 2/20 0.49
HSD17B10 Q99714 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
SLC5A1 P13866 2/20 0.49
SLC5A2 P31639 2/20 0.49
SLC16A3 O15427 1/20 0.49
TTR P02766 1/20 0.49
CYP1A2 P05177 1/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
CYP2D6 P10635 1/20 0.49
MAPT P10636 1/20 0.49
THRB P10828 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21100446 0.86 ALDH1A1 (0.53) KDM4EALDH1A1LMNATP53CYP3A4
SCHEMBL23758082 0.84 GFER (0.43) KDM4EALDH1A1GAARECQL
SCHEMBL107274 0.84 ALDH1A1 (0.55) ALDH1A1MEN1KMT2AHPGDTSHR
SCHEMBL106904 0.83 ESR1 (0.50) ESR1KDM4ECYP19A1ALDH1A1LMNA
SCHEMBL691976 0.81 TRPV1 (0.49) ESR1KDM4ECYP19A1ALDH1A1LMNA
SCHEMBL19520522 0.79 KDM4E (0.47) ESR1KDM4ECYP19A1ALDH1A1LMNA
SCHEMBL9255541 0.78 FFAR1 (0.65) LMNA
SCHEMBL19817614 0.77 MEN1 (0.46) ESR1KDM4EALDH1A1CYP3A4MEN1
SCHEMBL9258037 0.76 NPC1 (0.50) ESR1KDM4EALDH1A1LMNATP53
SCHEMBL29326623 0.76 PLAAT3 (0.44) ALDH1A1HSD17B10SLC5A1SLC5A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463374-A2 Isolated alcohol dehydrogenase enzymes and uses thereof Bio Architecture Lab, Inc. (US) 2012-06-13 EP claimed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 EP claimed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US claimed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US claimed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
EP-3230463-B2 RAPID PRETREATMENT APALTA PATENTS OUE (EE) 2025-07-16 EP disclosed
US-20240425893-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2024-12-26 US disclosed
US-12054761-B2 Rapid pretreatment Apalta Patents OÜ (EE) 2024-08-06 US disclosed
US-11821047-B2 High pressure zone formation for pretreatment Apalta Patent OÜ (EE) 2023-11-21 US disclosed
US-20230295678-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2023-09-21 US disclosed
EP-4098750-A1 RAPID PRETREATMENT Sweetwater Energy, Inc. (US) 2022-12-07 EP disclosed
EP-3230463-B1 RAPID PRETREATMENT SWEETWATER ENERGY INC (US) 2022-05-25 EP disclosed
US-20100086981-A1 COMPOSITIONS AND METHODS FOR IMPROVED SACCHARIFICATION OF BIOMASS QTEROS, INC. (US) 2010-04-08 US disclosed
US-20090203089-A1 ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF BIO ARCHITECTURE LAB, INC. (US) 2009-08-13 US disclosed
WO-2009097346-A2 ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF BIO ARCHITECTURE LAB, INC. (US) 2009-08-06 WO disclosed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US disclosed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US disclosed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090139134-A1 BIOFUEL PRODUCTION MGAM, DCXR, MANBA ESR1 3581/4885KDM4E 2777/4885CYP19A1 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.